Japanese regenerative medicine company developing high-quality platelets and other blood products from induced pluripotent stem (iPS) cells
Japanese regenerative medicine company developing high-quality platelets and other blood products from induced pluripotent stem (iPS) cells. Its goal is to enable safe, reliable, on-demand, affordable supply independent of blood donations. Its lead program, MEG-002, is allogeneic human iPS cell-derived HLA-homozygous platelets and has entered clinical testing.